Lyell Immunopharma (LYEL) Equity Ratio (2020 - 2026)

Lyell Immunopharma's Equity Ratio history runs 7 years deep, the most recent figure standing at 0.78 for Q1 2026.

• In Q1 2026, Equity Ratio changed 0.32% year-over-year to 0.78; the TTM figure through Mar 2026 stood at 0.78 (changed 0.32% YoY), while the FY2025 annual figure was 0.73, down 6.41% from the prior year.
• Equity Ratio came in at 0.78 for Q1 2026 at Lyell Immunopharma, up from 0.73 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.89 in Q1 2023 to a low of 0.73 in Q4 2025.
• A 5-year average of 0.83 and a median of 0.85 in 2022 frame the typical range for Equity Ratio.
• Across the five-year window, Equity Ratio gained 8.31% in 2023 and dropped 10.69% in 2024, its largest moves.
• Lyell Immunopharma's Equity Ratio stood at 0.89 in 2022, then slipped by 1.75% to 0.87 in 2023, then slipped by 10.69% to 0.78 in 2024, then dropped by 6.41% to 0.73 in 2025, then increased by 6.93% to 0.78 in 2026.
• According to Business Quant data, Equity Ratio over the past three periods registered 0.78, 0.73, and 0.81 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison